MedTrace Logo

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

NCT00471237 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 564

Last updated 2017-11-07

Study results available
· View outcomes & findings →

Summary

This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.

Conditions

Interventions

DRUG

Ronacaleret

100mg, 200mg, 300mg, 400mg

DRUG

Teriparatide

PTH (1-34)

DRUG

Alendronate

Bisphosphonate

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-14
Primary Completion
2008-12-26
Completion
2008-12-26

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Denmark
  • Germany
  • Hong Kong
  • Mexico
  • Norway
  • Poland
  • Russia
  • South Africa
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471237 on ClinicalTrials.gov